443 related articles for article (PubMed ID: 26080065)
1. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
Wobker SE; Kim LT; Hackman TG; Dodd LG
Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
[TBL] [Abstract][Full Text] [Related]
2. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
3. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
4. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
[TBL] [Abstract][Full Text] [Related]
5. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
[TBL] [Abstract][Full Text] [Related]
6. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
Adeniran AJ; Hui P; Chhieng DC; Prasad ML; Schofield K; Theoharis C
Acta Cytol; 2011; 55(6):570-5. PubMed ID: 22156468
[TBL] [Abstract][Full Text] [Related]
8. [Value of the detection of
Zhao H; Guo HQ; Zhang ZH; Cao J; Zhao LL; Sun Y; Wang C; Xiao T
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):18-22. PubMed ID: 30704164
[No Abstract] [Full Text] [Related]
9. Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
Smith AL; Williams MD; Stewart J; Wang WL; Krishnamurthy S; Cabanillas ME; Roy-Chowdhuri S
Cancer Cytopathol; 2018 Jun; 126(6):406-413. PubMed ID: 29579361
[TBL] [Abstract][Full Text] [Related]
10. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
Johnson SJ; Hardy SA; Roberts C; Bourn D; Mallick U; Perros P
Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
[TBL] [Abstract][Full Text] [Related]
11. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
[TBL] [Abstract][Full Text] [Related]
13. Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study.
Adeniran AJ; Theoharis C; Hui P; Prasad ML; Hammers L; Carling T; Udelsman R; Chhieng DC
Thyroid; 2011 Jul; 21(7):717-23. PubMed ID: 21568726
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas.
Proietti A; Borrelli N; Giannini R; Romani R; Di Coscio G; Quilici F; Rago T; Miccoli P; Vitti P; Basolo F
Cancer Cytopathol; 2014 Oct; 122(10):751-9. PubMed ID: 24913568
[TBL] [Abstract][Full Text] [Related]
15. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
[TBL] [Abstract][Full Text] [Related]
16. Assessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.
Dyhdalo K; Macnamara S; Brainard J; Underwood D; Tubbs R; Yang B
Cancer Cytopathol; 2014 Feb; 122(2):114-22. PubMed ID: 24150898
[TBL] [Abstract][Full Text] [Related]
17. Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma.
Brahma B; Yulian ED; Ramli M; Setianingsih I; Gautama W; Brahma P; Sastroasmoro S; Harimurti K
Asian Pac J Cancer Prev; 2013; 14(1):31-7. PubMed ID: 23534744
[TBL] [Abstract][Full Text] [Related]
18. Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.
Smith GD; Zhou L; Rowe LR; Jarboe EA; Collins BT; Bentz JS; Wittwer CT; Chadwick BE
Acta Cytol; 2011; 55(6):576-83. PubMed ID: 22156469
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E detection in cytological thyroid samples: A key component of the decision tree for surgical treatment of papillary thyroid carcinoma.
Collet JF; Lacave R; Hugonin S; Poulot V; Tassart M; Fajac A
Head Neck; 2016 Jul; 38(7):1017-21. PubMed ID: 26854757
[TBL] [Abstract][Full Text] [Related]
20. [BRAF V600E mutation in papillary thyroid carcinoma: prevalence and detection in fine needle aspiration specimens].
Dujardin F; Pagès JC; Collin C; de Calan L; Lecomte P; Guyétant S
Ann Pathol; 2010 Aug; 30(4):252-62. PubMed ID: 20837233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
